Jane Street’s Summit Therapeutics SMMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.9M Sell
230,700
-101,600
-31% -$1.52M ﹤0.01% 4087
2026
Q2
$4.84M Buy
332,300
+135,700
+69% +$2.41M ﹤0.01% 3762
2026
Q1
$3.73M Sell
196,600
-83,400
-30% -$1.35M ﹤0.01% 3974
2025
Q4
$4.9M Sell
280,000
-129,700
-32% -$2.44M ﹤0.01% 3252
2025
Q3
$8.46M Buy
409,700
+97,400
+31% +$2.36M ﹤0.01% 2634
2025
Q2
$6.65M Sell
312,300
-193,800
-38% -$4.42M ﹤0.01% 2642
2025
Q1
$9.8M Buy
506,100
+115,400
+30% +$2.32M ﹤0.01% 2017
2024
Q4
$6.97M Sell
390,700
-59,800
-13% -$1.16M ﹤0.01% 2262
2024
Q3
$9.9M Buy
450,500
+431,300
+2,246% +$6.03M ﹤0.01% 1926
2024
Q2
$150K Buy
+19,200
New +$104K ﹤0.01% 8572
2023
Q2
– Sell
-25,300
Closed -$44.3K – 9508
2023
Q1
$44.3K Sell
25,300
-12,300
-33% -$33.5K ﹤0.01% 8483
2022
Q4
$160K Buy
+37,600
New +$68.4K ﹤0.01% 7829

Other funds holding SMMT

Jane Street's SMMT Position: Q3 2026 in Review

Jane Street opened a new position in Summit Therapeutics (SMMT) in Q3 2026: 62,553 shares worth $1.06M. The stake represents ﹤0.01% of the portfolio and ranks #6374 among its holdings. This is a return to the name: Jane Street previously reported a position in SMMT as recently as Q2 2025.

Jane Street first reported a position in SMMT in Q4 2021 and has held it in 13 quarters since. The position peaked at $7.69M in Q3 2024. 296 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • Jane Street held 62,553 shares of Summit Therapeutics worth $1.06M as of Q3 2026.
  • Summit Therapeutics was a new Jane Street position in Q3 2026.
  • Summit Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q3 2026, its #6374 holding.
  • Jane Street first reported a position in Summit Therapeutics in Q4 2021 and has held it in 13 quarters since.
  • Jane Street's Summit Therapeutics position peaked at $7.69M in Q3 2024.
  • 296 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Jane Street's 13F filing for Q3 2026, filed 12 Nov 2026.